Pharmacogenetics-Guided Dose Modifications of Antidepressants

Clinics in Laboratory Medicine

Volumn 28, Issue 4, 2008, Pages 619-626

  Seeringer, Angela ^a   Kirchheiner, Julia ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; IMIPRAMINE; MAPROTILINE; MIANSERIN; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

BODY WEIGHT; COMORBIDITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 57049097080     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2008.05.006     Document Type: Review

References (34)

1. Kirchheiner J., Nickchen K., Bauer M., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9 5 (2004) 442-473
2. Kirchheiner J., Brosen K., Dahl M.L., et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104 3 (2001) 173-192
3. McLeod H.L., and Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3 1 (2002) 89-98
4. Mulder H., Heerdink E.R., van Iersel E.E., et al. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother 41 3 (2007) 408-413
5. Brøsen K., and Gram L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36 6 (1989) 537-547
6. Steimer W., Zopf K., von Amelunxen S., et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51 2 (2005) 376-385
7. Brockmoller J., Kirchheiner J., Schmider J., et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72 4 (2002) 438-452
8. Borgiani P., Ciccacci C., Forte V., et al. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8 11 (2007) 1545-1550
9. Kimura R., Miyashita K., Kokubo Y., et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120 2 (2007) 181-186
10. Chern H.D., Ueng T.H., Fu Y.P., et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 367 1-2 (2006) 108-113
11. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 7 (2005) 2329-2333
12. Hillman M.A., Wilke R.A., Caldwell M.D., et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14 8 (2004) 539-547
13. Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75 3 (2004) 204-212
14. Bauer M., Whybrow P.C., Angst J., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3 1 (2002) 5-43
15. Baumann P., Jonzier Perey M., Koeb L., et al. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1 2 (1986) 102-112
16. Laine K., Tybring G., Hartter S., et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 70 4 (2001) 327-335
17. Lam Y.W., Gaedigk A., Ereshefsky L., et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22 8 (2002) 1001-1006
18. Carrillo J.A., Dahl M.L., Svensson J.O., et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60 2 (1996) 183-190
19. Spigset O., Granberg K., Hagg S., et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 52 2 (1997) 129-133
20. Spigset O., Granberg K., Hagg S., et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 45 3 (1998) 257-263
21. Sindrup S.H., Brøsen K., Gram L.F., et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51 3 (1992) 278-287
22. Gram L.F., Guentert T.W., Grange S., et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 57 6 (1995) 670-677
23. Wang J.H., Liu Z.Q., Wang W., et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70 1 (2001) 42-47
24. Sindrup S.H., Brøsen K., Hansen M.G., et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15 1 (1993) 11-17
25. *D sample. PLoS ONE 3 4 (2008) e1872
26. *10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47 4 (1999) 450-453
27. Fukuda T., Nishida Y., Zhou Q., et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 56 (2000) 175-180
28. Otton S.V., Ball S.E., Cheung S.W., et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41 2 (1996) 149-156
29. Veefkind A.H., Haffmans P.M., and Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22 2 (2000) 202-208
30. Shams M.E., Arneth B., Hiemke C., et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31 5 (2006) 493-502
31. Lessard E., Yessine M., Hamelin B., et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9 (1999) 435-443
32. Rau T., Wohlleben G., Wuttke H., et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 75 5 (2004) 386-393
33. Grasmader K., Verwohlt P.L., Rietschel M., et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 60 5 (2004) 329-336
34. Kawanishi C., Lundgren S., Agren H., et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59 11 (2004) 803-807